- Home
- VNO vs ROIV Comparison
VNO vs ROIV Comparison
Compare VNO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNO | ROIV |
|---|---|---|
| Founded | 1946 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VNO | ROIV |
|---|---|---|
| Price | $33.70 | $22.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $37.67 | $24.31 |
| AVG Volume (30 Days) | 1.4M | ★ 8.2M |
| Earning Date | 02-09-2026 | 02-09-2026 |
| Dividend Yield | ★ 2.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.20 | N/A |
| Revenue | ★ $1,903,939,000.00 | $20,329,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.18 | $741.42 |
| P/E Ratio | $8.01 | ★ N/A |
| Revenue Growth | ★ 1.75 | N/A |
| 52 Week Low | $29.68 | $8.73 |
| 52 Week High | $45.37 | $23.47 |
Technical Indicators
Market Signals| Indicator | VNO | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 58.09 |
| Support Level | $32.67 | $21.60 |
| Resistance Level | $33.82 | $22.72 |
| Average True Range (ATR) | 0.86 | 0.82 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 33.61 | 61.77 |
Price Performance
Historical ComparisonAbout VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.